Geron (NASDAQ:GERN) Shares Up 4.5% – Here’s What Happened

Geron Corporation (NASDAQ:GERN – Get Free Report)’s share price was up 4.5% on Tuesday. The company traded as high as $0.9849 and last traded at $0.9840. 1,996,618 shares were traded during trading, a decline of 86% from the average session volume of 14,024,357 shares. The stock had previously closed at $0.9419.

Analysts Set New Price Targets

GERN has been the topic of a number of recent analyst reports. Needham & Company LLC lowered their price objective on Geron from $4.00 to $2.50 and set a “buy” rating on the stock in a research report on Wednesday, October 28th. Wedbush decreased their target price on shares of Geron to $5.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 28th. Finally, Weiss Ratings upgraded Geron from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, November 9th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $3.75.

Check Out Our Latest Stock Report on Geron

Geron Trading Up 6.7%

The company has a market capitalization of $647.46 million, a P/E ratio of -12.56 and a beta of 0.62. The company has a debt-to-equity ratio of 0.53, a current ratio of 6.31 and a quick ratio of 4.61. The stock’s 50 day moving average is $1.17 and its 200-day moving average is $1.40.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Nantahala Capital Management LLC bought a new position in Geron in the 2nd quarter worth about $15,648,000. Bank of America Corp DE bought a new stake in Geron in the 2nd quarter worth approximately $4,524,000. Edmond DE Rothschild Holding S.A. purchased a new stake in Geron during the 2nd quarter valued at $2,982,000. Janus Henderson Group PLC raised its stake in Geron by 826.7% during the 1st quarter. Janus Henderson Group PLC now owns 2,218,196 shares of the biopharmaceutical company’s stock valued at $3,304,000 after buying an additional 1,978,839 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of Geron by 144.1% during the 1st quarter. Renaissance Technologies LLC now owns 1,799,521 shares of the biopharmaceutical company’s stock valued at $2,681,000 after buying an additional 1,062,355 shares during the period. 73.71% of the stock is owned by hedge funds and other institutional investors.

Geron Company Profile

(Get Free Report)

Geron Corporation is a biopharmaceutical company focused on developing and commercializing therapies for blood disorders and cancers. Its lead product, Rytelo (imetelstat), is a telomerase inhibitor approved in the United States to treat certain adults with lower-risk myelodysplastic syndromes (MDS) who have transfusion-dependent anemia. Geron continues to develop imetelstat for potential use in other hematologic conditions. The company was founded in 1990 and is headquartered in Foster City, California.

Featured Stories

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.